Phase III study of doxorubicin/ cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 Trial - Eiermann, W (J Clin Oncol., 2011)
et al.